Hosted on MSN2mon
Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Furthering their analysis, the researchers tested the impact of PD-1 humanization in mice—replacing mouse PD-1 with the human version—through co-senior author Professor Jack Bui's laboratory ...
Nature4y
Novel immunotherapies to combine with PD-1/PD-L1 treatment
“Although current PD-1/ PD-L1-targeting treatments can achieve durable ... α interaction has been shown to inhibit tumor growth in mouse xenograft models. IMC-002 is a fully human IgG ...
EurekAlert!15d
Ability of large language models to extract PD-L1 biomarker details from electronic health records
A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from the electronic health ...
Physician's Weekly7d
PD-1/PD-L1 Inhibitors With Chemotherapy vs. Platinum-Based Treatment in Advanced Urothelial Cancer
The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...
Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
Precision Medicine Online15d
FDA Approves BeiGene's Tevimbra in First-Line PD-L1-Positive Esophageal Cancers
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
TMCnet9d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1, expanding the eligibility of ...
Medindia16d
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...
Finely tuned large language models can extract PD-L1 biomarker details from electronic health records
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from an electronic health record (EHR).